This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Qurient Co., Ltd.

Drug Names(s): Q203

Description: Q203 is an orally available potent anti-tuberculosis drug candidate that shows activity against both drug-sensitive and drug-resistant Mycobacterium tuberculosis. Q203 is a first-in-class agent with novel mode of action through blocking cytochrome bc1 complex.

Deal Structure: Infectex and Qurient
In February 2014, Infectex and Qurient have announced a license agreement granting Infectex exclusive rights to develop and commercialize Qurients Tuberculosis-fighting drug Q203 in the Russian Federation, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan and Ukraine.

Partners: Infectex

Q203 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug